UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.415

Sortiert nach

Neuropathology of mood disorders: do we see the stigmata of inflammation?

Translational psychiatry, 2016-11, Vol.6 (11), p.e946-e946

2016

Volltextzugriff (PDF)

Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play

Molecular psychiatry, 2013-05, Vol.18 (5), p.528-539

2013

Volltextzugriff (PDF)

Imaging phenotypes of major depressive disorder: genetic correlates

Neuroscience, 2009-11, Vol.164 (1), p.300-330

2009

Volltextzugriff (PDF)

The molecular genetics of cognition: dopamine, COMT and BDNF

Genes, brain and behavior, 2006-06, Vol.5 (4), p.311-328

2006

Volltextzugriff (PDF)

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

Neuropsychopharmacology (New York, N.Y.), 2024-08

2024

Volltextzugriff (PDF)

Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study

Journal of the American Academy of Child and Adolescent Psychiatry, 2015-02, Vol.54 (2), p.126-137.e1

2015

Volltextzugriff (PDF)

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Revista brasileira de psiquiatria, 2019-11, Vol.41 (6), p.499-510

2019

Volltextzugriff (PDF)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Neuropsychiatric disease and treatment, 2019-05, Vol.15, p.1365-1379

2019

Volltextzugriff (PDF)

Reproduced from Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study

Molecular psychiatry, 2013-05, Vol.18 (5), p.523-523

2013

Volltextzugriff (PDF)

An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia

Psychiatry research, 2016-02, Vol.236, p.47-52

2016

Volltextzugriff (PDF)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Neuropsychiatric disease and treatment, 2020-01, Vol.16, p.1533-1542

2020

Volltextzugriff (PDF)

Diets of Lake Michigan Salmon and Maximum Size of Alewife Prey

Journal of freshwater ecology, 2009-12, Vol.24 (4), p.563-566

Savitz, J.

2009

Volltextzugriff (PDF)

Personality endophenotypes for bipolar affective disorder: a family‐based genetic association analysis

Genes, brain and behavior, 2008-11, Vol.7 (8), p.869-876

2008

Volltextzugriff (PDF)

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

The international journal of neuropsychopharmacology, 2016-07, Vol.19 (7), p.pyw018

2016

Volltextzugriff (PDF)

Epistasis network centrality analysis yields pathway replication across two GWAS cohorts for bipolar disorder

Translational psychiatry, 2012-08, Vol.2 (8), p.e154-e154

2012

Volltextzugriff (PDF)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

Neuropsychiatric disease and treatment, 2019-01, Vol.15, p.731-737

2019

Volltextzugriff (PDF)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Neuropsychiatric disease and treatment, 2019-01, Vol.15, p.587-602

2019

Volltextzugriff (PDF)

Abstract # 1755 Sleep disturbance and kynurenine metabolism in a group of currently depressed, previously depressed, and never depressed subjects

Brain, behavior, and immunity, 2016-10, Vol.57, p.e14-e14

2016

Volltextzugriff (PDF)

Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study

International clinical psychopharmacology, 2017-11, Vol.32 (6), p.329

2017

Volltextzugriff (PDF)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

Neuropsychiatric disease and treatment, 2017-01, Vol.13, p.2193-2207

2017

Volltextzugriff (PDF)

Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder

Molecular psychiatry, 2011-04, Vol.16 (4), p.407-418

2011

Volltextzugriff (PDF)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

Neuropsychiatric disease and treatment, 2018-01, Vol.14, p.2807-2816

2018

Volltextzugriff (PDF)

45. Increased PBMC expression of inflammation and neurological disease-associated genes correlates with anhedonia, the BOLD response to masked happy faces and subgenual anterior cingulate cortex volume in patients with primary mood disorders

Brain, behavior, and immunity, 2012-09, Vol.26, p.S13-S13

2012

Volltextzugriff (PDF)

Lateralization of hand skill in bipolar affective disorder

Genes, brain and behavior, 2007-11, Vol.6 (8), p.698-705

2007

Volltextzugriff (PDF)

Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2009-07, Vol.34 (8), p.1885-1903

2009

Volltextzugriff (PDF)

1 – 25 von 1.415

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(559)
Mit Volltextzugriff
(1.336)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(379)
Life Sciences & Biomedicine
(364)
Humans
(319)
Stock Prices
(291)
Investments
(229)
Female
(209)
Adult
(148)
Biological And Medical Sciences
(137)
Medical Sciences
(125)
Pregnancy
(118)
Semiconductors
(117)
Internet Stocks
(116)
Male
(113)
Public, Environmental & Occupational Health
(111)
Software
(109)
Investment Policy
(102)
Corporate Profits
(92)
Computer Industry
(91)
Neurosciences & Neurology
(91)
Manycompanies
(90)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Neuropathology of mood disorders: do we see the stigmata of inflammation?

Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play

Imaging phenotypes of major depressive disorder: genetic correlates

The molecular genetics of cognition: dopamine, COMT and BDNF

Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Reproduced from Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study

An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies

Diets of Lake Michigan Salmon and Maximum Size of Alewife Prey

Personality endophenotypes for bipolar affective disorder: a family‐based genetic association analysis

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

Epistasis network centrality analysis yields pathway replication across two GWAS cohorts for bipolar disorder

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Abstract # 1755 Sleep disturbance and kynurenine metabolism in a group of currently depressed, previously depressed, and never depressed subjects

Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

45. Increased PBMC expression of inflammation and neurological disease-associated genes correlates with anhedonia, the BOLD response to masked happy faces and subgenual anterior cingulate cortex volume in patients with primary mood disorders

Lateralization of hand skill in bipolar affective disorder

Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia

Suchergebnisse filtern